Valion Bio, Inc (TIVC) Fair Value & Analysis
Healthcare · US · Market cap $4.0M
Valion Bio, Inc
TIVC · US
Fair value as of: Jul 21, 2026
From 1 valuation models · updated today
Fair value updated Jul 21, 2026, revised from $10.00 to $1.54 (−84.6%) since Jun 24, 2026. Share price −28.2% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.5140 – $4.38 · fair‑value band $1.15 – $2.29 · the $0.5500 price screens below the $1.54 fair value. As of Jul 21, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Valion Bio, Inc (TIVC) currently trades at $0.5500, while our model-based Fair Value estimate is $1.54, implying the stock looks roughly 180.0% undervalued today. We read business quality at 11/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Trailing-twelve-month revenue stands at $482K. Revenue grew 15.9% year over year. It earns a return on equity of -82.7%. The balance sheet holds a net cash position of $6.2M. Fundamentals as of Jul 21, 2026
Our scenario range runs from $1.15 (bear case) to $2.29 (bull case); at $0.5500, the current price sits below that range. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at 180%, TIVC screens cheaper than that median.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 21, 2026. TTM = trailing twelve months.
About the company
Valion Bio, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Valion Bio, Inc reported revenue of $382K in FY2025 versus $1.2M in FY2021, a compound −24.3%/yr. Reported net income was −$8.9M in FY2025.
Is TIVC fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $86.97 | $69.36 | -20% |
| Stryker Corporation SYK | $305.66 | $187.83 | -39% |
| Medtronic plc MDTC34 | R$210.63 | R$24.08 | -89% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EWL | €74.64 | €31.98 | -57% |
| Siemens Healthineers AG SEMHF | $39.91 | $48.29 | +21% |
| DexCom, Inc DXCM | $74.77 | $53.93 | -28% |
| GE HealthCare Technologies Inc GEHC | $61.99 | $48.34 | -22% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥141.85 | ¥147.63 | +4% |
| Koninklijke Philips N.V PHG | $26.61 | $12.54 | -53% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Valion Bio, Inc (TIVC) undervalued?
What is the fair value of TIVC?
What is the quality score of TIVC?
What is the revenue of Valion Bio, Inc (TIVC)?
What is the net profit margin of TIVC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Tell me when Valion Bio, Inc reaches its Fair Value
Just your email, and we'll notify you when the price and Fair Value of Valion Bio, Inc materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.